Submissions from 2025
64775 Integrated Safety Update of Abrocitinib in 1014 Young Adult Patients Aged 18 to <40 Years With Moderate-to-Severe Atopic Dermatitis: Data From More Than 2250 Patient-Years With up to 4.5 Years of>Exposure, Eric Simpson, Alan D. Irvine, Jonathan I. Silverberg, Linda F. Stein Gold, Michael J. Cork, Mette Deleuran, Bob Geng, Cristina Lumpan, Andrew Selfridge, Haiyun Fan, and Herwig Koppensteiner
Anti-IL-15 treatment results in greater repigmentation in vitiligo than placebo in participants who receive phototherapy and reduces circulating terminally differentiated cytotoxic CD8 memory cells, Dawn Smilek, Laura Cooney, Marc Lytle, Karen Boyle, Matthew Sherman, Noha Lim, Wendy Gao, Ling Li, Carolyn Bromstead, Patricia Tosta, David Rosmarin, Jeffrey Sobell, Anand Ganesan, Iltefat Hamzavi, George Han, Victor Huang, Mehdi Rashighi, and Brett King
0152 IFNg-mediated reprogramming of antigen presenting cell (IMRAPC) behavior in keratinocytes is perturbed in skin cancer, Niharika Srivastava, Angelica Guardia De Diego, Mohammad H. Barmal, Indra Adrianto, Jesse Veenstra, and Cristina de Guzman Strong
63324 Efficacy of zasocitinib (TAK-279), an oral, allosteric, potent and selective TYK2 inhibitor, evaluated by Physician's Global Assessment×Body surface area (PGA×BSA), in a randomized phase 2b trial in moderate-to-severe plaque psoriasis, Linda F. Stein Gold, Lawrence Green, Jessamyn Blau, Wenwen Zhang, Jonathan Uy, Warren Winkelman, and Leon Kircik
63474 The VISIBLE study: Burden of comorbidities in participants with moderate-to-severe psoriasis across all skin tones, Linda F. Stein Gold, George Han, Mona Shahriari, Olivia Choi, Theodore Alkousakis, Tony Ma, Daphne Chan, Lawrence Green, Aaron Farberg, Shawn G. Kwatra, and Andrew Alexis
63046 Tapinarof Cream 1% Once Daily for Atopic Dermatitis: Validated Investigator Global Assessment for Atopic Dermatitis™ x Body Surface Area (vIGA-AD™xBSA) Composite in Two Pivotal Phase 3 Trials in Adults and Children Down to 2 Years of Age, Linda F. Stein Gold, Rocco T. Serrao, G. Michael Lewitt, Anna M. Tallman, David S. Rubenstein, and Philip M. Brown
63736 SPECTREM: Guselkumab Demonstrates Consistent Significant Clearance Across the Full Range of Low Body Surface Area, Moderate Psoriasis With Special Sites Involvement, Linda F. Stein Gold, Bruce Strober, April W. Armstrong, Theodore Alkousakis, Kim A. Papp, Richard Langley, Olivia Choi, Daphne Chan, Jenny Jeyarajah, Vlada Groysman, and Mark G. Lebwohl
CO144 Improvements in Scalp Outcomes With Roflumilast Foam 0.3% for Psoriasis of the Scalp and Body From the Phase 3 ARRECTOR Trial, Linda F. Stein Gold, Bruce Strober, Ron Vender, Raj Chovatiya, April Armstrong, David Krupa, Jennifer C. Jaworski, Melissa S. Seal, Diane Hanna, DNP DCNP Brett, and Stephenson PharmD
IMPROVEMENTS IN SCALP OUTCOMES WITH ROFLUMILAST FOAM 0.3% FOR PSORIASIS OF THE SCALP AND BODY FROM THE PHASE 3 ARRECTOR TRIAL, Linda F. Stein Gold, Bruce Strober, Ron Vender, Raj Chovatiya, April Armstrong, David Krupa, Jennifer C. Jaworski, Melissa S. Seal, Diane Hanna, and Brett Stephenson
VPS72 primes B-lymphoid gene expression and limits myeloid output during hematopoietic stem cell development, Kalpana Subedi, Jie Wang, Qing-Sheng Mi, and Li Zhou
Tapinarof Cream 1% Once Daily: Consistent Efficacy Across All Body Regions, Including Head And Neck, In Adults And Children Down 2 Years Of Age With Atopic Dermatitis, Anna Tallman, Justin Greiwe, J. Wesley Sublett, Adelaide Hebert, David Rosmarin, Philip Brown, David Rubenstein, and Linda F. Stein Gold
LEBRIKIZUMAB IMPROVES ATOPIC DERMATITIS AND QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB: RESULTS FROM THE ADAPT STUDY, Elisabeth H. Taudorf, Jonathan Silverberg, Lindsay Ackerman, Jerry Bagel, Linda F. Stein Gold, Andrew Blauvelt, David Rosmarin, Raj Chovatiya, Matthew Zirwas, Gil Yosipovitch, Jill Waibel, Jenny Murase, Ben Lockshin, Jamie Weisman, and Eric Simpson
62860 Achievement of treat-to-target thresholds for overall psoriasis response with deucravacitinib: post hoc, subgroup analysis of the randomized, double-blind, placebo-controlled phase 3b/4 PSORIATYK SCALP trial, Diamant Thaci, Kristina C. Duffin, Linda F. Stein Gold, Leon Kircik, Andrew Napoli, Chun-Yen Cheng, Rachel Dyme, Eugene Balagula, and Matthias Augustin
Absolute EASI response achieved by lebrikizumab over 16 weeks in patients with moderate-to-severe atopic dermatitis, Diamant Thaçi, Lluis Puig, Kim Papp, Linda F. Stein Gold, Pablo Fernández-Peñas, Yu-Huei Huang, Martin Dossenbach, Meritxell Falqués, Helena Agell, Franziska Schönherr, and Christian Vestergaard
61710 Dermatology pathways programs and increasing provider representation, Reinie Thomas, Marina Khreizat, Brittany Lane, Karan Pandher, Severine Cao, Henry W. Lim, and Natalie H. Matthews
Comorbidities Associated with Cutaneous Lichen Planus: A Systematic Review, Sara Trumza, Dema Boutany, and Andrina Paul
MEAN ABSOLUTE EASI AND PRURITUS ACHIEVED BY LEBRIKIZUMAB OVER 16 WEEKS IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS, Christian Vestergaard, Diamant Thaci, Luis Puig, Kim A. Papp, Linda F. Stein Gold, Pablo F. Peñas, Yu-Huei Huang, Martin Dossenbach, Meritxell Falques, Helena Agell, and Kristian Gaarn Du Jardin
0650 Dysregulated innate MAIT cells in patients with hidradenitis suppurativa, Ping Wang, Jugmohit Toor, Peter Dimitrion, Iltefat Hamzavi, Indra Adrianto, Qing-Sheng Mi, and Li Zhou
63960 Surgical location affects preoperative anxiety in Mohs micrographic surgery: a prospective interventional study, Josiah Williams, Veronica Emmerich, Shane Reynal, Courtney Heron, Stephanie Snyder, Matthew Johnson, Rima Ghamrawi, Emily Unrue, and Steven Feldman
64991 Surgical location affects preoperative anxiety in Mohs micrographic surgery: an interventional study, Josiah Williams, Veronica Emmerich, Shane Reynal, Courtney Heron, Stephanie Snyder, Matthew Johnson, Rima Ghamrawi, Emily Unrue, Jessica Savas, Phillip Williford, and Steven Feldman
LONG-TERM EFFICACY AND SAFETY OF NEMOLIZUMAB UP TO 2 YEARS IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: PIVOTAL TRIAL SUBGROUP ANALYSIS OF THE ARCADIA LTE, Andreas Wollenberg, Jonathan I. Silverberg, Diamant Thaci, Marie Tauber, Linda Stein Gold, Marjolein S. De Bruin-Weller, Matthias Augustin, Adam Reich, Matthew J. Zirwas, Liliana Ulianov, Anna Ryzhkova, Soo Yeon Cheong, and Christophe Pikett
63916 Idiopathic CD4+ T Cell lymphocytopenia associated with a chronic recalcitrant erythroderma resembling pityriasis rubra pilaris, Nikita Wong, Karan Pandher, and Ben J. Friedman
Disease-Specific Barriers to Breast Cancer Screening Guideline Adherence among Hidradenitis Suppurativa Patients, Mulin Xiong, Albert Young, Umer Nadir, Alexandra Turfe, Meyer Gershater, and Qing-Sheng Mi
62644 Analysis of Popular Sunscreens for Babies and Children: Ingredient Profiles and Marketing Tactics, Marissa Yaldo, Meghan Mansour, Hailey Olds, and Geoffrey Potts
0519 Involucrin-casein kinase 1e-vitamin D receptor is a functional regulatory axis for human skin evolution and diversity, Yao Yao, Autumn Hicks, A. Schmidt, M. Mathyer, and Cristina de Guzman Strong
61429 Adherence to melanoma surveillance guidelines: real-world practice and implications for patient outcomes, Albert T. Young, Rita El Jbeily, Brittany N. Lane, Katia Hermes, Madison Romanski, Flavio Ago, Andrea Dai, J. Gregory Hixon, Martin A. Weinstock, Charles N. Ellis, and Natalie H. Matthews
0278 Whole blood RNA-Seq identifies key pathways linked to TNF-α-inhibitor failure in patients with hidradenitis suppurativa, Albert T. Young, Randy Mi, Ping Wang, Anuradha Bishnoi, Andrea Dai, Kermanjot S. Sidhu, Suzanne Shoffner-Beck, Jeffrey Cruz, Sahil Kapur, Li Zhou, Indra Adrianto, and Qing-Sheng Mi
62587 Adherence to Breast Cancer Screening Guidelines Among Patients with Hidradenitis Suppurativa: A Retrospective Cohort Study, Albert T. Young, Umer Nadir, Alexandra Turfe, Meyer Gershater, Mulin Xiong, and Qing-Sheng Mi
61220 Analysis of patients with hidradenitis suppurativa from a large, single-center Detroit cohort: a retrospective cross-sectional study of 13,130 patients over a 27-year period, Kelly Young, Ian Loveless, Wan-Ting Su, Jesse Veenstra, Li Zhou, Iltefat Hamzavi, Indra Adrianto, and Qing-Sheng Mi
ZL-1503: A bispecific antibody targeting inflammatory and pruritogenic pathways with a prolonged serum half-life and sustained activity in non-human primates, L. Zhang, S. Yan, X. Dai, B. Wan, Q. Ye, W. Peng, Y. Ge, W. Li, X. Fang, S. Li, Z. Wen, X. Tan, H. Du, B. Qi, L. Wang, P. Huang, Linda F. Stein Gold, P. Charuworn, and L. Liu
VPS72 Controls Regulatory T Cell Adaptation and Stability in the Tumor Microenvironment, Li Zhou, Kalpana Subedi, Jie Wang, Jugohit Toor, and Qing-Sheng Mi
Submissions from 2024
51125 PATIENT EXIT INTERVIEWS ILLUSTRATE BENEFIT OF TRIFAROTENE ON ACNE-INDUCED PIGMENTARY PROBLEMS, Andrew Alexis, James Del Rosso, Seth Forman, Antonio Calatayud, John Browning, Vivian Laquer, J. P. York, Rajeev Chavda, Sunil Dhawan, Angela Moore, and Linda Stein-Gold
53113 Trifarotene shown to improve acne and related sequelae (scars, pigmentation), Andrew Alexis, Stephen Schleicher, Jonathan Weiss, Valerie Callender, J. P. York, Rajeev Chavda, Fran E. Cook Bolden, Neal Bhatia, James Del Rosso, and Linda Stein-Gold
53447 Phase IV studies show trifarotene is efficacious and suitable for broad range of patient types, Andrew Alexis, Linda Stein-Gold, Rajeev Chavda, J. P. York, James Del Rosso, and Jonathan Weiss
54147 Efficacy of Ruxolitinib Cream for Treatment of Atopic Dermatitis in Children Aged 2–<12 Years by Baseline Clinical Characteristics: Subgroup Analysis From a Randomized Phase 3 Study>(TRuE-AD3), April W. Armstrong, Lawrence F. Eichenfield, Lara W. Lee, Kanwaljit K. Brar, Joel C. Joyce, Seth B. Forman, Weily Soong, Howard Sofen, Brett Angel, Qian Li, and Linda Stein-Gold
Dermatology personal statement themes and match outcomes, Redina Bardhi, L. Bugosh, M. Al-Hadidi, J. Duong, S. Colbert, B. Jones, and S. Daveluy
54396 Ultrasound Mapping for Carbon Dioxide Surgery in Hidradenitis Suppurativa, Redina Bardhi, Mohsen Mokhtari, Mavra Masood, Iltefat Hamzavi, and Indermeet Kohli
52726 Bimekizumab impact on concomitant rescue interventions in patients with moderate to severe hidradenitis suppurativa in BE HEARD I & II, Falk G. Bechara, Christopher Sayed, Stephanie Goldberg, Jacek C. Szepietowski, Philippe Guillem, Iltefat Hamzavi, Pratiksha Dokhe, Paulatsya Joshi, Robert Rolleri, Leah Davis, and Hessel H. van der Zee
53894 Roflumilast foam 0.3% once daily in patients with seborrheic dermatitis: Improvement in patient reported outcomes and pruritus from a phase 3 trial (STRATUM), Neal Bhatia, Fran Cook-Bolden, Janet DuBois, Laura Ferris, Linda Stein-Gold, Irina Turchin, Matthew Zirwas, David Krupa, Patrick Burnett, David R. Berk, and David H. Chu
Ruxolitinib cream 1.5% twice daily for the treatment of extensive atopic dermatitis in children aged 2-11 years: 52 week results from a maximum-use trial, Robert Bissonnette, Mark S. Lee, Seth B. Forman, Linda F. Stein Gold, Howard Kallender, Brett Angel, Yutzu Kuo, and Amy S. Paller
Tapinarof cream 1% once daily: Interim analysis of ADORING 3 phase 3 long-term extension trial in adults and children down to age 2 years with atopic dermatitis, Robert Bissonnette, Linda F. Stein Gold, Leon Kircik, Lawrence F. Eichenfield, H. Chih-Ho Hong, Kim A. Papp, Anna M. Tallman, Stephen C. Piscitelli, David S. Rubenstein, Philip M. Brown, and Jonathan I. Silverberg
53928 Tapinarof Cream 1% Once Daily: Interim Analysis of ADORING 3 Phase 3 Long-term Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis, Robert Bissonnette, Linda Stein-Gold, Leon Kircik, Lawrence F. Eichenfield, H. Chih-Ho Hong, Kim A. Papp, Anna M. Tallman, Stephen C. Piscitelli, David S. Rubenstein, Philip M. Brown, and Jonathan I. Silverberg
Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis, Christopher G. Bunick, Neal Bhatia, James Del Rosso, Zoe D. Draelos, Lawrence F. Eichenfield, Leon H. Kircik, Mark G. Lebwohl, Melinda Gooderham, Lawrence J. Green, Adelaide A. Hebert, Ronald B. Vender, Matthew Zirwas, Eric L. Simpson, Linda F. Stein Gold, Melissa Seal, Scott Snyder, David W. Osborne, Patrick Burnett, Robert C. Higham, David H. Chu, and David R. Berk
50584 Online Continuing Medical Education Improved Dermatologists’ Knowledge, Competence, and Confidence About New Topical Treatments for Psoriasis, Shari Dermer, Christine Considine, Karen Badal, and Linda Stein-Gold
54214 Efficacy of Ruxolitinib Cream for the Treatment of Atopic Dermatitis in Children Aged 2–<12 Years by Previous Medication History: Subgroup Analysis From the>Randomized, Phase 3 TRuE-AD3 Study, Shari Dermer, Christine Considine, Karen Badal, and Linda Stein-Gold
Global survey reveals demand for additional photoprotection education in Australia...Cancer Nurses Society of Australia (CNSA) 26th Annual Congress, June 19-21, 2024, Brisbane, Queensland, L. Dousset, K. Khosrotehrani, P. Guitera, T. Passeron, B. Dreno, Henry W. Lim, D. Kerob, and J. Krutmann
Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with moderate and/or more extensive atopic dermatitis: subgroup analysis from the TRuE-AD3 study, Lawrence F. Eichenfield, April W. Armstrong, Linda F. Stein Gold, Andrea L. Zaenglein, Lara Wine Lee, Kanwaljit K. Brar, Joel C. Joyce, Kristen E. Holland, Brett Angel, Daniel Sturm, Qian Li, and Eric L. Simpson
51626 Psychometric Properties of the Vitiligo Noticeability Scale (VNS) Using Data From a Phase 2 Upadacitinib Study in Adults With Nonsegmental Vitiligo, Khaled Ezzedine, Ahmed M. Soliman, Heidi S. Camp, Mary Kate Ladd, Robin Pokrzywinski, Rohini Sen, Bethanee J. Schlosser, Jung Min Bae, and Iltefat Hamzavi
Treatment efficacy in patients with moderate-to-severe atopic dermatitis who switched from dupilumab to abrocitinib in JADE EXTEND, a phase 3 long-term extension study, Melinda J. Gooderham, Stephan Weidinger, Eric L. Simpson, Mette Deleuran, Linda F. Stein Gold, Saleem A. Farooqui, Pinaki Biswas, Gary Chan, Erman Güler, and Herwig Koppensteiner
53495 Disparity of cost and protective features between tinted and non-tinted sunscreens, Judy Hamad, Christopher Chung, Henry W. Lim, and Natalie H. Matthews
PCR163 Treatment Priorities and Unmet Need Among Adults and Adolescents With Non-Segmental Vitiligo in the United States, Iltefat Hamzavi, J. Coulter, A. Balaji, L. Franco, S. Darnell, E. Law, S. Kurosky, R. Adiri, N. Elbuluk, and B. Hauber
51618 Reliability, Validity, Responsiveness, and Meaningful Change Thresholds of the Facial–Vitiligo Area Scoring Index (F-VASI) and Total–Vitiligo Area Scoring Index (T-VASI) Among Patients with Non-Segmental Vitiligo, Iltefat Hamzavi, Ahmed M. Soliman, Heidi S. Camp, Mary Kate Ladd, Robin Pokrzywinski, Rohini Sen, Bethanee J. Schlosser, Jung Min Bae, and Khaled Ezzedine
54585 Vitiligo, Nutrition and the Gut Microbiome: A Narrative Review, Marlee Hewitt, Karan Pandher, Nada Elbuluk, and Richard Huggins
Environment impacts the phenotypic severity of flaky tail, MC903-induced inflammation, and dysbiosis in filaggrin-null mice, Autumn Hicks, Mohammed H. M Bharmal, A. Schmidt, Q Zheng, Congcong Yin, Peter Dimitrion, Qing-Shing Mi, Emelia Grice, Indra Adrianto, and Cristina de Guzman Strong
54843 QR Codes and Dermatology: Examining Resident Attitudes on Digitized After Visit Summaries, Mustufa Jafry, Joseph Fakhoury, and Holly Kerr
54853 Trends in Incidence and Mortality of Pleomorphic Dermal Sarcoma: A Retrospective Cohort Study Using SEER Data, Mustufa Jafry and Molly Powers
54772 Pigmentary disorders, prevalence, impact on quality of life and social stigmatization: Results of the first large international survey, Delphine Kerob, Thierry Passeron, Andrew Alexis, Brigitte Dreno, Liu Wei, Akimichi Morita, Chee Leok, Susana Puig, Sergio Schalka, and Henry W. Lim
54542 Assessing the risk of subcutaneous nodules, Rachel Krevh, Redina Bardhi, Karan Pandher, Gordon Jacobsen, and Laurie Kohen
53329 Long-Term Adverse Event Risks of Systemic Janus Kinase (JAK) Inhibitors versus Traditional Immunomodulators, Olivia Lamberg, Karan Pandher, and Henry Lim
51652 Safety and efficacy of risankizumab in adult patients with moderate to severe plaque psoriasis with non-pustular palmoplantar involvement: change in DLQI and achievement of DLQI 0/1 results from the Phase 3b IMMprint trial, Mark Lebwohl, Michael Bukhalo, Linda Stein-Gold, Michelle Pelle, Bradley Glick, Maria Llamas-Velasco, Samuel Sanchez-Rivera, Tianyu Zhan, Leonidas Drogaris, Ramon Espaillat, and Robert Bissonnette
51675 Safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with non-pustular palmoplantar involvement: changes in PPASI and PASI from Phase 3b IMMprint trial, Mark Lebwohl, Michael Bukhalo, Linda Stein-Gold, Michelle Pelle, Bradley Glick, Mar Llamas-Velasco, Samuel Sanchez-Rivera, Tianyu Zhan, Leonidas Drogaris, Ramon Espaillat, and Robert Bissonnette
52818 Easy on the Hands: Utilization of a Foot Pedal for Tumescent Anesthesia Delivery, Mavra Masood, Joseph Fakhoury, Angela Parks-Miller, and Iltefat Hamzavi
52910 Projected burden of melanoma clinical surveillance in the United States, Natalie Matthews, Judy Hamad, James Henderson, Angela Mariotto, Martin Weinstock, and Charles Ellis
50532 VISIBLE: Guselkumab Demonstrated Significant Scalp Psoriasis Clearance and Scalp Itch Improvements at Week 16 in Skin of Color Participants With Moderate-to-Severe Plaque Psoriasis, Amy McMichael, Linda Stein-Gold, Jennifer Soung, Chesahna Kindred, Olivia Choi, Daphne Chan, Jenny Jeyarajah, Candrice R. Heath, Tina Bhutani, Maxwell Sauder, and Andrew Alexis
54078 Examining Hair Preservation in Manual vs. Machine Scalp Cooling by Chemotherapy Regimen: A Meta-Analysis, Abena Minta, Sarah Shareef, Patrick Schnell, Trevor Nessel, Lucy Rose, Brittany Dulmage, and Taylor Novice
52736 Assessment of Color Match of Universal Tinted Sunscreens in Fitzpatrick Skin Phototypes I-VI, Mohsen Mokhtari, Redina Bardhi, Mavra Masood, Deena Abdel-Gadir, Dorothea McGowan, Brittany N. Lane, Marissa Ceresnie, Henry Lim, Iltefat Hamzavi, Indermeet Kohli, and Tasneem Mohammad
52503 The financial burden of scalp cooling therapy: a non-profit organization data analysis, Madison Novice, Taylor Novice, Molly Powers, and Kristen L. Sicco
52509 Expanding access to scalp cooling therapy: a review of post-capping satisfaction in patients who received financial assistance from a non-profit organization, Madison Novice, Lucy Rose, Taylor Novice, Allison Darland, Brittany Dulmage, Molly Powers, and Kristen L. Sicco
54337 Full-body Multifocal Pyoderma Gangrenosum in the setting of PASH Syndrome, Sandra Oska, Sasank Konda, and Natalie Matthews
Transforming Growth Factor β-activated Kinase 1 Controls Langerhans Cell Homeostasis through Autophagic Machinery, Nirmal Parajuli, Q. Wang, Q. Yu, James Ge, Qing-Shing Mi, and Li Zhou
Efficacy and safety of upadacitinib in a phase 2 randomized, double-blind, dose-ranging study of adults with extensive non-segmental vitiligo, Thierry Passeron, Khaled Ezzedine, Iltefat H. Hamzavi, Nanja van Geel, Bethanee J. Schlosser, Xiaofei Hu, Xiaohong Huang, David Rosmarin, John E. Harris, Heidi S. Camp, and Amit G. Pandya
50250 Comparing the Effect of Risankizumab versus Apremilast on Psoriasis Symptoms, Treatment Satisfaction, and Health-Related Quality of Life from the Phase 4 IMMpulse Study, Andreas Pinter, Linda Stein-Gold, Jerry Bagel, Stephen K. Tyring, Ronald Vender, Adam Reich, Lev Pavlovsky, Mark I. Kaldas, Tianshuang Wu, Manish Patel, and Kim A. Papp
Sustained improvements over 140 weeks in signs, symptoms, and quality of life with upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis: integrated results from the phase 3 Measure Up 1 and Measure Up 2 studies, Vimal H. Prajapati, Christopher G. Bunick, Kilian Eyerich, Linda F. Stein Gold, Fabrizio Galimberti, Brian Calimlim, Henrique Teixeira, Xiaofei Hu, Yang Yang, Cristina Sancho, Ayman Grada, and Alan D. Irvine
50524 Facebook groups provide support and product recommendations for patients using scalp cooling to prevent chemotherapy-induced alopecia: A survey study, Lucy Rose, Madison Novice, Abena Minta, Taylor Novice, and Brittany Dulmage
51716 Hydroquinone and Alternative Agents for Hyperpigmentation: A Systematic Review, Kavya Shivaram, Katherine Edwards, and Tasneem Mohammad
53146 Expert evidence regarding cosmetic procedures in minors, Victoria Shi, Umer Nadir, Misha Haq, Eric Koza, Areeba Ahmed, Melissa Ma, David Ozog, Kristen Kelly, Andrew Krakowski, and Murad Alam
Efficacy and safety of upadacitinib vs dupliumab in adults and adolescents with moderate-to-severe atopic dermatitis: results of an open-label, efficacy assessor-blinded head-to-head phase 3b/4 study (Level Up), Jonathan I. Silverberg, Christopher Bunick, H. Chih-ho Hong, Pedro Mendes-Bastos, Linda F. Stein Gold, Antonio Costanzo, Nadia Ibrahim, Cristina Sancho, Xiaoqiang Wu, Yu Han, Gweneth Levy, Kathy Altman, and Kilian Eyerich
Tapinarof cream 1% once daily: significant efficacy in the treatment of atopic dermatitis in two pivotal phase 3 trials in adults and children down to 2 years of age, Jonathan I. Silverberg, Lawrence F. Eichenfield, Adelaide A. Hebert, Eric Simpson, Linda F. Stein Gold, Robert Bissonnette, Kim A. Papp, John Browning, Pearl Kwong, Neil J. Korman, Philip M. Brown, David S. Rubenstein, Stephen C. Piscitelli, Matthew C. Somerville, Anna M. Tallman, and Leon Kircik
Efficacy and safety of upadacitinib through 140 weeks in adolescents and adults with moderate-to-severe atopic dermatitis: phase 3 randomized clinical trial results, Jonathan I. Silverberg, Emma Guttman-Yassky, Eric L. Simpson, Kim A. Papp, Andrew Blauvelt, Chia-Yu Chu, H. Chih-ho Hong, Linda F. Stein Gold, Thomas Bieber, Kenji Kabashima, David Rosmarin, Amy Gamelli, Brian Calimlim, Namita Vigna, Xiaofei Hu, Yang Yang, Xiaoqiang Wu, Xiaohong Huang, Smitha Suravaram, Henrique D. Teixeira, Eliza Raymundo, and Alan D. Irvine
A novel efficacy index for long-term therapy outcomes expressed by maintenance of EASI 75 and IGA 0,1 response in atopic dermatitis, Jonathan I. Silverberg, Alan Irvine, Peter Foley, James Del Rosso, Alexander Schacht, Martin Dossenbach, Marta Casillas, Erin Johansson, Gaia Gallo, and Linda F. Stein Gold
Nemolizumab elicits fast itch response in atopic dermatitis within 2 days: a post hoc analysis of ARCADIA 1 and 2 data, Jonathan I. Silverberg, Linda F. Stein Gold, Diamant Thaçi, Andrew E. Pink, Kim A. Papp, Franz J. Legat, Vivian T. Laquer, Soo Yeon Cheong, Liliana Ulianov, Anna Ryzhkova, and Christophe Piketty
Characteristics of adult patients with atopic dermatitis initiating biologics and JAK inhibitors in the CorEvitas AD Registry, Eric Simpson, Christian Fenske, Alvin Li, Zach Dawson, Yolanda Muñoz Maldonado, Kaylee Ho, Kayla Callahan, Linda F. Stein Gold, Seemal Desai, Alexandra Golant, Douglas DiRuggiero, and Jonathan I. Silverberg
50377 Factors associated with the initiation of a new systemic therapy among adults with atopic dermatitis: Data from the CorEvitas Atopic Dermatitis Registry, Eric Simpson, Alvin Li, Zach Dawson, Kaylee Ho, Linda Stein-Gold, Seemal Desai, Alexandra Golant, Douglas DiRuggiero, and Jonathan Silverberg
Rapid and early onset of itch relief with tapinarof cream 1% once daily in two pivotal phase 3 trials in adults and children down to two years of age with atopic dermatitis, Eric Simpson, Jonathan I. Silverberg, Robert Bissonnette, Linda F. Stein Gold, April Armstrong, Adelaide A. Hebert, Rocco T. Serrao, Jeannette R. Jakus, Philip M. Brown, David S. Rubenstein, Stephen C. Piscitelli, Anna M. Tallman, and Lawrence F. Eichenfield
52792 Lebrikizumab provides stable skin response with no or minimal fluctuations for up to two years in patients with atopic dermatitis, Jonathan Sliverberg, Andreas Wollenberg, Peter Lio, Jose M. Carrascosa, Marta Casillas, Gaia Gallo, Yuxin D. Fan, Emily Yang, Christian Vestergaard, Linda Stein-Gold, and James Del Rosso
Identifying disparities in phototherapy dosing and research participation among patients with psoriasis by race, ethnicity, and skin phototype: Findings from the light treatment effectiveness study, W. B. Song, B. Bishop, R. Fitzsimmons, A. Bridges, U. Nehal, D. Shin, Henry W. Lim, J. Takeshita, L. Howard, K. Duffin, and J. Gelfand
51480 Efficacy of apremilast in adults with mild-to-moderate plaque psoriasis with scalp involvement: Pooled data from PROMINENT, ADVANCE, and EMBRACE trials, Linda Stein-Gold, Matthias Augustin, Howard Sofen, Paolo Gisondi, Shauna Jardon, Jyotsna Reddy, Henry Zou, and Kristina Callis Duffin
51091 Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in plaque psoriasis: 3-year Psoriasis Area and Severity Index (PASI) outcomes in the long-term extension of the phase 3 POETYK PSO-1 and PSO-2 trials, Linda Stein-Gold, Subhashis Banerjee, Matthew J. Colombo, Renata M. Kisa, Victoria Berger, Kim Hoyt, Jennifer Soung, Tiago Torres, Neal Bhatia, Brad P. Glick, and Mark D. Kaufmann
53949 Tapinarof Cream 1% Once Daily was Well Tolerated for the Treatment of Adults and Children Down to 2 Years of Age with Moderate to Severe Atopic Dermatitis Across Two Pivotal Phase 3 Trials, Linda Stein-Gold, James Del Rosso, Benjamin D. Ehst, Matthew J. Zirwas, Lawrence J. Green, Philip M. Brown, Anna M. Tallman, David S. Rubenstein, and Stephen C. Piscitelli
Amlitelimab (an anti-OX40 ligand antibody) vs placebo in patients with moderate-to-severe atopic dermatitis: study design of phase 3 OCEANA clinical trials COAST 1/2, SHORE, AQUA, and ESTUARY, Linda F. Stein Gold, Stephan Weidinger, Delphine Staumont-Salle, Saeko Nakajima, Eric L. Simpson, Marjolein de Bruin Weller, Sonya Davey, Kassim Rahawi, and Charlotte Bernigaud
53779 Fixed-Combination Halobetasol Propionate 0.01%/Tazarotene 0.045% and Halobetasol Propionate 0.01% Lotions for Plaque Psoriasis on Lower Extremities With Body Hair, Linda Stein-Gold, Edward Lain, George Han, and Abby Jacobson
50351 Lebrikizumab maintains clinically meaningful outcomes with treatment administered every 4 weeks in adult and adolescent patients with moderate-to-severe atopic dermatitis, Linda Stein-Gold, Marie L. Schuttelaar, Vimal H. Prajapati, Bernhard Homey, Lindsay Strowd, Martin Dossenbach, Chunyuan Liu, Jinglin Zhong, Evangeline Pierce, Helena Agell, and Juan F. Silvestre
53803 Early and Sustained Efficacy of Fixed-Combination Halobetasol Propionate and Tazarotene Lotion in Participants with Moderate-to-Severe Scaling or Plaque Elevation, Linda Stein-Gold, Emil Tanghetti, Edward Lain, Andrea Murina, and Abby Jacobson
52041 Safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis: integrated analysis from 10 clinical trials, Linda Stein-Gold, Diamant Thaci, Norito Katoh, Vivian Shi, Alan Irvine, Maria L. Buziqui Piruzeli, Sonia Montmayeur, Gaia Gallo, and Marjolein de Bruin-Weller
50251 Efficacy of Risankizumab Versus Apremilast Among Patients with Scalp or Nail Psoriasis from the Phase 4 IMMpulse Study, Linda Stein-Gold, Stephen K. Tyring, H. Chih-ho Hong, Lev Pavlovsky, Andreas Pinter, Adam Reich, Tianshuang Wu, Vassilis Stakias, Sven Richter, and Kim A. Papp
54203 VISIBLE: Clearance and Symptom Improvement With Guselkumab at Week 16 in Skin of Color Participants With Moderate-to-Severe Plaque Psoriasis, Linda Stein-Gold, Jensen Yeung, Adrian O. Rodriguez, Jessica Vasquez, Olivia Choi, Katelyn Rowland, Theodore Alkousakis, Jenny Jeyarajah, Javier Alonso-Llamazares, Stephen Tyring, and April W. Armstrong
REAL WORLD EFFECTIVENESS OF INITIATING TOPICAL THERAPY COMPARED WITH INITIATING APREMILAST EARLY OR LATE, Bruce Strober, Linda F. Stein Gold, Paolo Gisondi, Kate Orroth, Myriam Cordey, Shia T. Kent, Cynthia Deignan, Shauna Jardon, Rohini K. Hernandez, M. Alan Brookhart, and April Armstrong
REAL WORLD EFFECTIVENESS of INITIATING TOPICAL THERAPY COMPARED with INITIATING APREMILAST EARLY or LATE, Bruce Strober, Linda F. Stein Gold, Paolo Gisondi, Kate Orroth, Myriam Cordey, Shia T. Kent, Cynthia Deignan, Shauna Jardon, Rohini K. Hernandez, M. Alan Brookhart, and April Armstrong
DEUCRAVACITINIB IN PLAQUE PSORIASIS: MAINTENANCE OF RESPONSE OVER 3 YEARS, B. Strober, H. Sofen, S. Imafuku, C. Paul, M. Gooderham, L. Spelman, S. J. Seo, T. Passeron, R. M. Kisa, V. Berger, E. Vritzali, K. Hoyt, M. J. Colombo, S. Banerjee, M. Augustin, Linda F. Stein Gold, A. Alexis, D. Thaçi, A. Blauvelt, and M. Lebwohl
JMJD3 promotes MAIT cell thymic egress and differentiation into MAIT17 cells, Jugmohit Toor, Jie Wang, Tingting Liu, Kalpana Subedi, Rachel Krevh, Congcong Yin, James Ge, Bobby Zuniga, Li Zhou, and Qing-Sheng Mi
